Director at $NTRA Sells 676 Shares in Insider Sale

Jonathan Sheena, a director at $NTRA, recently sold 676 shares of the company, amounting to about $122,137. This transaction amounted to roughly 2.3% of the shares he held in this class of stock. After the sale, Sheena retained 28,782 shares of this particular class of $NTRA stock.

Over the last 6 months, insiders at $NTRA have been actively trading the company’s stock on the open market. Out of 203 trades within this period, all 203 have been sales, with no insider purchases recorded. Notable individuals like Matthew Rabinowitz, the Executive Chairman, have made 14 sales of 112,436 shares, totaling approximately $18,755,165. Similarly, Steven Leonard Chapman, the CEO and President, has made 27 sales of 70,362 shares, raking in an estimated $10,335,759. Jonathan Sheena, in addition to his recent sale, has executed a total of 73 sales of 45,517 shares, totaling around $7,372,537. Other key figures within the company, such as Daniel Rabinowitz, Solomon Moshkevich, Gail Boxer Marcus, Michael Burkes Brophy, John Fesko, and Rowan E Chapman, have similarly engaged in selling shares over the last 6 months.

In terms of hedge fund activity, 374 institutional investors increased their holdings of $NTRA stock, while 329 decreased their positions in the most recent quarter. Noteworthy moves included JPMorgan Chase & Co adding 3,263,822 shares to their portfolio, representing a 44.3% increase valued at around $551,390,088. On the other hand, Citadel Advisors LLC removed 1,301,513 shares from their holdings, amounting to a significant 61.3% decrease valued at approximately $219,877,606. These actions indicate a dynamic and evolving landscape of institutional investments in $NTRA.

Congressional stock trading involving $NTRA has seen some activity over the past 6 months, with one purchase and one sale recorded. Representative Josh Gottheimer has been actively trading $NTRA stock, making a purchase worth up to $15,000 on 08/22 and executing a sale of equal value on 07/22. These transactions highlight the interest and involvement of members of Congress in trading $NTRA stock.

Analyst ratings for $NTRA have predominantly been positive, with 6 firms issuing buy ratings on the stock in recent months. Notable firms like Stephens & Co., Piper Sandler, Barclays, RBC Capital, Evercore ISI Group, and UBS have all issued favorable ratings for $NTRA. These assessments reflect a generally optimistic outlook on the company’s performance and future prospects. Additionally, multiple analysts have provided price targets for $NTRA, with a median target of $210.0. Target prices set by analysts like Brandon Couillard, Mason Carrico, David Westenberg, Luke Sergott, Conor McNamara, Daniel Markowitz, and Elizabeth Garcia further contribute to the diverse range of projections for $NTRA’s valuation.